General Information of Drug (ID: DMHZPJ0)

Drug Name
ISIS 18078 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
TTD Drug ID
DMHZPJ0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 Discovery agent N.A. Investigative [2]
AS-601245 DMQ95EB Discovery agent N.A. Investigative [3]
Aminopyridine deriv. 2 DM94KQP Discovery agent N.A. Investigative [2]
IN-1166 DMMS6D3 Discovery agent N.A. Investigative [4]
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG Discovery agent N.A. Investigative [2]
JNK-IN-8 DMLWYJB Discovery agent N.A. Investigative [5]
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide DMSAD87 Discovery agent N.A. Investigative [2]
AC1LG8KT DMFKV97 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Not Available [1]

References

1 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
2 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
3 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
4 Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
5 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
6 N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.